Preclinical advances enhance CAR-T therapy effectiveness in acute myeloid leukemia, suggesting improved survival outcomes.
Multidimensional technological innovation and the synergistic optimization of combination therapies are critical to overcoming AML-specific barriers. These advances hold the potential to unlock the precise clinical application of CAR-T therapy, ultimately improving survival outcomes for patients with relapsed/refractory AML.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: